[
  {
    "problem_id": "11",
    "premise": "A 72-year-old man presents with sudden onset of right-sided weakness and slurred speech. CT scan shows an acute left middle cerebral artery territory infarct. The attending physician attributes the symptoms to low blood sugar and starts glucose infusion.",
    "statement": "The patient has an ischemic stroke.",
    "label": "entailment",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. CT scan (instrumented data) shows acute left MCA infarct - highest evidence tier. 2. Physician's hypoglycemia attribution (opinion) contradicts imaging. 3. Acute cerebral infarct on imaging directly confirms ischemic stroke regardless of clinical interpretation. 4. Reject lower-tier opinion conflicting with objective imaging. 5. Statement matches CT findings.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. CT scan (instrumented data) shows acute left MCA infarct - highest evidence tier. 2. Physician's hypoglycemia attribution (opinion) contradicts imaging. 3. Acute cerebral infarct on imaging directly confirms ischemic stroke regardless of clinical interpretation. 4. Reject lower-tier opinion conflicting with objective imaging. 5. Statement matches CT findings.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "12",
    "premise": "A 48-year-old woman reports progressive shortness of breath and swelling in her legs over several weeks. Echocardiogram reveals severely reduced left ventricular ejection fraction. The cardiologist diagnoses asthma and prescribes inhalers.",
    "statement": "The patient has heart failure.",
    "label": "entailment",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. Premise contains conflicting claims: echocardiogram (instrumented data) shows severely reduced LVEF (objective evidence for heart failure) vs. cardiologist's diagnosis of asthma (clinician opinion).\n2. Evidence hierarchy prioritizes echocardiogram measurements over diagnostic opinions.\n3. Severely reduced LVEF (<40%) is a cardinal diagnostic criterion for heart failure with reduced ejection fraction (HFrEF).\n4. Asthma diagnosis contradicts objective cardiac dysfunction evidence and fails to explain peripheral edema.\n5. Clinician opinion is rejected due to conflict with higher-tier evidence.\n6. Statement aligns with echocardiogram findings and symptom profile.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Premise contains conflicting claims: echocardiogram (instrumented data) shows severely reduced LVEF (objective evidence for heart failure) vs. cardiologist's diagnosis of asthma (clinician opinion).\n2. Evidence hierarchy prioritizes echocardiogram measurements over diagnostic opinions.\n3. Severely reduced LVEF (<40%) is a cardinal diagnostic criterion for heart failure with reduced ejection fraction (HFrEF).\n4. Asthma diagnosis contradicts objective cardiac dysfunction evidence and fails to explain peripheral edema.\n5. Clinician opinion is rejected due to conflict with higher-tier evidence.\n6. Statement aligns with echocardiogram findings and symptom profile.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "13",
    "premise": "A 30-year-old man presents with high fever, severe headache, neck stiffness, and photophobia. Lumbar puncture reveals cloudy cerebrospinal fluid with elevated white cell count and low glucose. The physician attributes symptoms to tension headache and prescribes analgesics.",
    "statement": "The patient has bacterial meningitis.",
    "label": "entailment",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "Objective CSF findings (cloudy fluid, elevated WBC, low glucose) strongly indicate bacterial meningitis (highest evidence tier). The physician's tension headache diagnosis (opinion tier) contradicts instrumented data. Core principles prioritize lab results over clinician opinion. CSF abnormalities definitively support bacterial meningitis diagnosis, making the statement entailed despite conflicting clinician assessment.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "Objective CSF findings (cloudy fluid, elevated WBC, low glucose) strongly indicate bacterial meningitis (highest evidence tier). The physician's tension headache diagnosis (opinion tier) contradicts instrumented data. Core principles prioritize lab results over clinician opinion. CSF abnormalities definitively support bacterial meningitis diagnosis, making the statement entailed despite conflicting clinician assessment.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "14",
    "premise": "A 62-year-old woman experiences sudden loss of vision in one eye. Fundoscopic examination reveals a pale retina with a cherry-red spot at the macula. The ophthalmologist suspects conjunctivitis and prescribes antibiotic drops.",
    "statement": "The patient has central retinal artery occlusion.",
    "label": "entailment",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. Objective fundoscopic findings (pale retina with cherry-red spot) are instrumented data (highest evidence tier) pathognomonic for central retinal artery occlusion. 2. Ophthalmologist's conjunctivitis diagnosis (clinician opinion) contradicts objective findings. 3. Sudden vision loss aligns with CRAO, not conjunctivitis. 4. Resolve conflict by prioritizing objective findings over clinician opinion. 5. Statement matches highest-tier evidence.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Objective fundoscopic findings (pale retina with cherry-red spot) are instrumented data (highest evidence tier) pathognomonic for central retinal artery occlusion. 2. Ophthalmologist's conjunctivitis diagnosis (clinician opinion) contradicts objective findings. 3. Sudden vision loss aligns with CRAO, not conjunctivitis. 4. Resolve conflict by prioritizing objective findings over clinician opinion. 5. Statement matches highest-tier evidence.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "15",
    "premise": "A 54-year-old male presents with severe epigastric pain radiating to the back, elevated serum lipase, and abdominal CT confirming pancreatic inflammation. The clinician diagnoses gastritis and starts proton pump inhibitors.",
    "statement": "The patient has acute pancreatitis.",
    "label": "entailment",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "Objective evidence (elevated lipase + CT-confirmed pancreatic inflammation + characteristic pain) meets diagnostic criteria for acute pancreatitis (highest evidence tier). Clinician's gastritis diagnosis (opinion tier) conflicts with imaging/lab evidence. Hierarchy prioritizes instrumented data over clinical opinion. Statement aligns with verified evidence.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "Objective evidence (elevated lipase + CT-confirmed pancreatic inflammation + characteristic pain) meets diagnostic criteria for acute pancreatitis (highest evidence tier). Clinician's gastritis diagnosis (opinion tier) conflicts with imaging/lab evidence. Hierarchy prioritizes instrumented data over clinical opinion. Statement aligns with verified evidence.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "16",
    "premise": "A 45-year-old man complains of chest discomfort after meals and occasional regurgitation. Endoscopy is normal. Despite the absence of cardiac symptoms, the physician diagnoses myocardial infarction and starts anticoagulation therapy.",
    "statement": "The patient has myocardial infarction.",
    "label": "contradiction",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. Objective evidence: Endoscopy (instrumented data) shows normal results. No cardiac symptoms reported (clinician observation).\n2. Lower credibility claim: Physician's MI diagnosis (opinion) contradicts absence of cardiac symptoms and presence of postprandial discomfort (GERD-typical pattern).\n3. MI diagnosis requires objective cardiac evidence (ECG changes, troponin elevation) not mentioned. Anticoagulation initiation doesn't validate diagnosis.\n4. Conflict resolved by prioritizing instrumented data (normal endoscopy) and symptom pattern over unsupported diagnostic opinion.\n5. Statement contradicts remaining consistent evidence.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Objective evidence: Endoscopy (instrumented data) shows normal results. No cardiac symptoms reported (clinician observation).\n2. Lower credibility claim: Physician's MI diagnosis (opinion) contradicts absence of cardiac symptoms and presence of postprandial discomfort (GERD-typical pattern).\n3. MI diagnosis requires objective cardiac evidence (ECG changes, troponin elevation) not mentioned. Anticoagulation initiation doesn't validate diagnosis.\n4. Conflict resolved by prioritizing instrumented data (normal endoscopy) and symptom pattern over unsupported diagnostic opinion.\n5. Statement contradicts remaining consistent evidence.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "17",
    "premise": "A 28-year-old woman presents with diffuse abdominal pain, bloating, and irregular bowel movements for several months. Colonoscopy is unremarkable. The physician diagnoses colon cancer and refers her for chemotherapy.",
    "statement": "The patient has colon cancer.",
    "label": "contradiction",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. Premise contains conflicting claims: unremarkable colonoscopy (instrumented evidence) vs physician's colon cancer diagnosis (opinion).\n2. Colonoscopy is the gold standard diagnostic tool for colon cancer detection (evidence hierarchy: instrumented > opinion).\n3. Unremarkable colonoscopy directly contradicts cancer diagnosis.\n4. Physician's opinion cannot override objective negative findings.\n5. Statement 'has colon cancer' is contradicted by higher-evidence colonoscopy result.",
        "pred": "contradiction",
        "fact_verification": "fact_verification_error",
        "reasoning_verification": "reasoning_verification_error",
        "overall_verification": false
      },
      {
        "reasoning": "1. Parse premise: Colonoscopy (instrumented evidence) shows no abnormalities vs physician's diagnosis (opinion) of colon cancer.\n2. Apply evidence hierarchy: Instrumented colonoscopy (gold standard for cancer detection) > clinician opinion.\n3. Detect conflict: Normal colonoscopy directly contradicts cancer diagnosis.\n4. Resolve conflict: Reject lower-credibility physician opinion as invalid against objective test results.\n5. Conclusion: No valid evidence supports cancer diagnosis; statement contradicts highest-credibility evidence.",
        "pred": "contradiction"
      }
    ],
    "solution_final": {
      "reasoning": "1. Parse premise: Colonoscopy (instrumented evidence) shows no abnormalities vs physician's diagnosis (opinion) of colon cancer.\n2. Apply evidence hierarchy: Instrumented colonoscopy (gold standard for cancer detection) > clinician opinion.\n3. Detect conflict: Normal colonoscopy directly contradicts cancer diagnosis.\n4. Resolve conflict: Reject lower-credibility physician opinion as invalid against objective test results.\n5. Conclusion: No valid evidence supports cancer diagnosis; statement contradicts highest-credibility evidence.",
      "pred": "contradiction"
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "18",
    "premise": "A 61-year-old woman arrives with gradual onset of numbness and tingling in her feet. Nerve conduction studies are normal. The neurologist diagnoses Guillain\u2013Barr\u00e9 syndrome and admits her for IVIG therapy.",
    "statement": "The patient has Guillain\u2013Barr\u00e9 syndrome.",
    "label": "contradiction",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. Premise contains conflicting claims: neurologist's diagnosis of Guillain-Barr\u00e9 syndrome (clinician opinion) vs normal nerve conduction studies (instrumented data).\n2. Evidence hierarchy prioritizes objective test results over clinician opinions.\n3. Guillain-Barr\u00e9 syndrome typically requires abnormal nerve conduction studies for diagnosis (albuminocytologic dissociation in CSF is also typical but not mentioned here).\n4. Normal nerve conduction studies directly contradict pathophysiological expectations for GBS.\n5. Clinician's diagnosis appears inconsistent with objective evidence.\n6. Conflict resolved in favor of instrumented data - reject diagnosis.",
        "pred": "contradiction",
        "fact_verification": "incorrect",
        "reasoning_verification": "correct",
        "overall_verification": false
      },
      {
        "reasoning": "1. Premise contains neurologist's diagnosis of Guillain-Barr\u00e9 syndrome (clinician opinion) and normal nerve conduction studies (instrumented data).\n2. Corrected factual basis: Normal NCS doesn't exclude early GBS (supported by clinical guidelines), removing the prior incorrect assumption that abnormal NCS is required.\n3. No direct conflict remains since normal NCS can coexist with early GBS diagnosis.\n4. Evidence hierarchy maintains instrumented data (NCS) as higher than clinician opinion, but here they're not mutually exclusive.\n5. Diagnosis persists as a clinical judgment supported by symptom presentation (numbness/tingling) despite normal NCS.\n6. No higher-evidence contradiction exists; clinician's diagnosis stands as the best available evidence.",
        "pred": "entailment"
      }
    ],
    "solution_final": {
      "reasoning": "1. Premise contains neurologist's diagnosis of Guillain-Barr\u00e9 syndrome (clinician opinion) and normal nerve conduction studies (instrumented data).\n2. Corrected factual basis: Normal NCS doesn't exclude early GBS (supported by clinical guidelines), removing the prior incorrect assumption that abnormal NCS is required.\n3. No direct conflict remains since normal NCS can coexist with early GBS diagnosis.\n4. Evidence hierarchy maintains instrumented data (NCS) as higher than clinician opinion, but here they're not mutually exclusive.\n5. Diagnosis persists as a clinical judgment supported by symptom presentation (numbness/tingling) despite normal NCS.\n6. No higher-evidence contradiction exists; clinician's diagnosis stands as the best available evidence.",
      "pred": "entailment"
    },
    "is_correct": false,
    "error_info": []
  },
  {
    "problem_id": "19",
    "premise": "A 39-year-old man reports intense thirst, frequent urination, and unexplained weight loss. Fasting blood glucose is 98 mg/dL, and HbA1c is within normal range. The physician diagnoses type 1 diabetes mellitus.",
    "statement": "The patient has type 1 diabetes mellitus.",
    "label": "contradiction",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "Objective measurements (fasting glucose 98 mg/dL [normal <100], normal HbA1c) directly conflict with type 1 diabetes diagnosis criteria (requires hyperglycemia). Physician's opinion is lower evidence tier than lab values. Reject diagnosis due to contradiction with instrumented data.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "Objective measurements (fasting glucose 98 mg/dL [normal <100], normal HbA1c) directly conflict with type 1 diabetes diagnosis criteria (requires hyperglycemia). Physician's opinion is lower evidence tier than lab values. Reject diagnosis due to contradiction with instrumented data.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "20",
    "premise": "A 56-year-old man presents with persistent cough and hemoptysis. Chest CT is clear, with no evidence of masses or infiltrates. The physician diagnoses lung cancer and begins chemotherapy.",
    "statement": "The patient has lung cancer.",
    "label": "contradiction",
    "gt_problem_type": "epsitemic",
    "solution_history": [
      {
        "reasoning": "1. Premise contains conflicting claims: objective chest CT (no masses/infiltrates) vs physician's diagnosis of lung cancer. 2. CT imaging (instrumented data) ranks higher than clinician opinion in evidence hierarchy. 3. Lung cancer diagnosis without radiographic evidence contradicts objective findings. 4. Clear CT scan directly opposes typical lung cancer presentation requiring visible lesions. 5. Reject lower-hierarchy clinician opinion in favor of imaging evidence.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Premise contains conflicting claims: objective chest CT (no masses/infiltrates) vs physician's diagnosis of lung cancer. 2. CT imaging (instrumented data) ranks higher than clinician opinion in evidence hierarchy. 3. Lung cancer diagnosis without radiographic evidence contradicts objective findings. 4. Clear CT scan directly opposes typical lung cancer presentation requiring visible lesions. 5. Reject lower-hierarchy clinician opinion in favor of imaging evidence.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "31",
    "premise": [
      "Adverse Events 9:",
      " Total: 48/72 (66.67%)",
      " Diarrhea 30/72 (41.67%)",
      " Neutropenic sepsis 3/72 (4.17%)",
      " Gastrointestinal bleeding 2/72 (2.78%)",
      " Hypokalemia 4/72 (5.56%)",
      " Injection site reaction 6/72 (8.33%)",
      " Pulmonary embolism 2/72 (2.78%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of diarrhea.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": null,
    "solution_final": null,
    "is_correct": false,
    "error_info": [
      {
        "error_info": "Error on id 31: sequence item 0: expected str instance, list found",
        "location": "framework/skipping_planner.py:157"
      }
    ]
  },
  {
    "problem_id": "32",
    "premise": [
      "Adverse Events 10:",
      " Total: 42/66 (63.64%)",
      " Fever 22/66 (33.33%)",
      " Anaphylaxis 2/66 (3.03%)",
      " Ischemic stroke 1/66 (1.52%)",
      " Atrial fibrillation 3/66 (4.55%)",
      " Hypotension 4/66 (6.06%)",
      " Nausea 5/66 (7.58%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of fever.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": null,
    "solution_final": null,
    "is_correct": false,
    "error_info": [
      {
        "error_info": "Error on id 32: sequence item 0: expected str instance, list found",
        "location": "framework/skipping_planner.py:157"
      }
    ]
  },
  {
    "problem_id": "33",
    "premise": [
      "Adverse Events 11:",
      " Total: 36/58 (62.07%)",
      " Rash 18/58 (31.03%)",
      " Stevens-Johnson syndrome 1/58 (1.72%)",
      " Acute hepatic failure 2/58 (3.45%)",
      " Elevated liver enzymes 5/58 (8.62%)",
      " Pruritus 7/58 (12.07%)",
      " Headache 4/58 (6.90%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of rash.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": null,
    "solution_final": null,
    "is_correct": false,
    "error_info": [
      {
        "error_info": "Error on id 33: sequence item 0: expected str instance, list found",
        "location": "framework/skipping_planner.py:157"
      }
    ]
  },
  {
    "problem_id": "34",
    "premise": [
      "Adverse Events 12:",
      " Total: 44/64 (68.75%)",
      " Cough 19/64 (29.69%)",
      " Pneumonitis 4/64 (6.25%)",
      " Respiratory failure 2/64 (3.13%)",
      " Sepsis 3/64 (4.69%)",
      " Hyponatremia 5/64 (7.81%)",
      " Dizziness 6/64 (9.38%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of cough.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": null,
    "solution_final": null,
    "is_correct": false,
    "error_info": [
      {
        "error_info": "Error on id 34: sequence item 0: expected str instance, list found",
        "location": "framework/skipping_planner.py:157"
      }
    ]
  },
  {
    "problem_id": "35",
    "premise": [
      "Adverse Events 13:",
      " Total: 60/90 (66.67%)",
      " Arthralgia 28/90 (31.11%)",
      " Torsades de pointes 1/90 (1.11%)",
      " Ventricular tachycardia 2/90 (2.22%)",
      " Pancreatitis 3/90 (3.33%)",
      " Acute kidney injury 5/90 (5.56%)",
      " Fatigue 10/90 (11.11%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of arthralgia.",
    "label": "contradiction",
    "gt_problem_type": "risk",
    "solution_history": null,
    "solution_final": null,
    "is_correct": false,
    "error_info": [
      {
        "error_info": "Error on id 35: sequence item 0: expected str instance, list found",
        "location": "framework/skipping_planner.py:157"
      }
    ]
  },
  {
    "problem_id": "36",
    "premise": "A 38-year-old woman reports an abrupt 'worst headache of my life' that began during a high-intensity spin class, followed by brief nausea and neck stiffness. She is alert and oriented with no focal neurological deficits on examination. She has not yet had any neuroimaging or lumbar puncture.",
    "statement": "Subarachnoid hemorrhage must be urgently excluded.",
    "label": "entailment",
    "gt_problem_type": "risk",
    "solution_history": [
      {
        "reasoning": "1. Extract candidates: Subarachnoid hemorrhage (SAH) is explicitly mentioned in the statement and implied in the premise by 'worst headache of my life' + neck stiffness (classic SAH presentation).\n2. Likelihood: High clinical suspicion given thunderclap headache onset during exertion (spin class), though absence of focal deficits lowers probability. Not ruled out (no neuroimaging/LP done).\n3. Severity: Catastrophic (high mortality if untreated).\n4. Risk calculation: High severity (life-threatening) \u00d7 moderate likelihood (classic presentation despite normal exam) = high expected harm.\n5. Statement evaluation: SAH exclusion requires urgent neuroimaging (CT head \u00b1 LP). Since this hasn't been done, the premise leaves SAH unexcluded. The statement's recommendation aligns with risk mitigation for this high-severity unruled-out hazard.\n6. Management implication: Failure to exclude SAH would risk missing a time-sensitive catastrophic diagnosis. The statement's urgency is clinically appropriate.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract candidates: Subarachnoid hemorrhage (SAH) is explicitly mentioned in the statement and implied in the premise by 'worst headache of my life' + neck stiffness (classic SAH presentation).\n2. Likelihood: High clinical suspicion given thunderclap headache onset during exertion (spin class), though absence of focal deficits lowers probability. Not ruled out (no neuroimaging/LP done).\n3. Severity: Catastrophic (high mortality if untreated).\n4. Risk calculation: High severity (life-threatening) \u00d7 moderate likelihood (classic presentation despite normal exam) = high expected harm.\n5. Statement evaluation: SAH exclusion requires urgent neuroimaging (CT head \u00b1 LP). Since this hasn't been done, the premise leaves SAH unexcluded. The statement's recommendation aligns with risk mitigation for this high-severity unruled-out hazard.\n6. Management implication: Failure to exclude SAH would risk missing a time-sensitive catastrophic diagnosis. The statement's urgency is clinically appropriate.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "37",
    "premise": "A 27-year-old woman presents with lower abdominal pain predominantly on the right, light vaginal spotting, and new shoulder-tip pain. Last menstrual period was approximately 6 weeks ago. She feels lightheaded when standing but is hemodynamically stable. No pregnancy test or imaging has been done yet.",
    "statement": "Urgent pelvic ultrasound and quantitative \u03b2-hCG testing are required to exclude ectopic pregnancy.",
    "label": "entailment",
    "gt_problem_type": "risk",
    "solution_history": [
      {
        "reasoning": "1. Extract candidates: Ectopic pregnancy (plausible latent diagnosis) is a key risk due to classic symptoms (abdominal pain, vaginal bleeding, shoulder-tip pain suggesting hemoperitoneum), amenorrhea. No pregnancy test/imaging means it remains unruled out.\n2. Likelihood: High clinical suspicion (symptoms align with ectopic pregnancy presentation).\n3. Severity: Life-threatening (risk of rupture with hemorrhage, hypovolemic shock).\n4. Risk assessment: High (likely \u00d7 catastrophic outcome). The statement proposes necessary diagnostic steps to exclude this high-risk condition. Failure to perform these would leave a severe hazard unaddressed.\n5. Management implication: Without ultrasound/\u03b2-hCG, ectopic pregnancy cannot be excluded, making urgent testing required to mitigate risk. The statement directly addresses the dominant risk.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract candidates: Ectopic pregnancy (plausible latent diagnosis) is a key risk due to classic symptoms (abdominal pain, vaginal bleeding, shoulder-tip pain suggesting hemoperitoneum), amenorrhea. No pregnancy test/imaging means it remains unruled out.\n2. Likelihood: High clinical suspicion (symptoms align with ectopic pregnancy presentation).\n3. Severity: Life-threatening (risk of rupture with hemorrhage, hypovolemic shock).\n4. Risk assessment: High (likely \u00d7 catastrophic outcome). The statement proposes necessary diagnostic steps to exclude this high-risk condition. Failure to perform these would leave a severe hazard unaddressed.\n5. Management implication: Without ultrasound/\u03b2-hCG, ectopic pregnancy cannot be excluded, making urgent testing required to mitigate risk. The statement directly addresses the dominant risk.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "38",
    "premise": "A 34-year-old woman, two weeks postpartum, presents with sudden pleuritic chest pain and shortness of breath. Heart rate is 118 bpm, SpO2 92% on room air, and she reports mild calf discomfort after prolonged car travel yesterday. Chest auscultation is clear and a prior chest X-ray from triage was unremarkable. No D-dimer or CT pulmonary angiography has been performed.",
    "statement": "Pulmonary embolism requires urgent exclusion.",
    "label": "entailment",
    "gt_problem_type": "risk",
    "solution_history": [
      {
        "reasoning": "1. Candidates: Pulmonary embolism (PE) is a key adverse event given postpartum status (hypercoagulable state), sudden pleuritic pain, tachycardia, hypoxemia, and calf discomfort (possible DVT). No definitive exclusion via CTPA/D-dimer. 2. Likelihood: Elevated due to Wells criteria elements (postpartum, signs/symptoms) but not quantified. 3. Severity: PE is life-threatening (high severity). 4. Risk assessment: High severity \u00d7 non-zero likelihood (not ruled out) \u2192 substantial risk. 5. Statement evaluation: 'Requires urgent exclusion' aligns with risk mitigation for a high-severity, plausible condition. Failure to exclude PE would expose patient to catastrophic risk. Thus, the statement is entailed by the premise's risk profile.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Candidates: Pulmonary embolism (PE) is a key adverse event given postpartum status (hypercoagulable state), sudden pleuritic pain, tachycardia, hypoxemia, and calf discomfort (possible DVT). No definitive exclusion via CTPA/D-dimer. 2. Likelihood: Elevated due to Wells criteria elements (postpartum, signs/symptoms) but not quantified. 3. Severity: PE is life-threatening (high severity). 4. Risk assessment: High severity \u00d7 non-zero likelihood (not ruled out) \u2192 substantial risk. 5. Statement evaluation: 'Requires urgent exclusion' aligns with risk mitigation for a high-severity, plausible condition. Failure to exclude PE would expose patient to catastrophic risk. Thus, the statement is entailed by the premise's risk profile.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "39",
    "premise": "A 55-year-old man with acute severe low back pain reports numbness in the perineal ('saddle') area, difficulty initiating urination, and bilateral leg weakness that worsened over 12 hours. Reflexes are reduced at the ankles. He has not had any spinal imaging or bladder scan yet.",
    "statement": "Emergency MRI of the lumbosacral spine is required to exclude cauda equina syndrome.",
    "label": "entailment",
    "gt_problem_type": "risk",
    "solution_history": [
      {
        "reasoning": "1. Extract candidates: The premise describes classic red flags for cauda equina syndrome (CES) - saddle anesthesia, urinary retention, bilateral leg weakness, and reduced reflexes. CES (B) is a critical latent diagnosis. 2. Likelihood: High clinical suspicion (multiple key symptoms present). CES remains unexcluded as no imaging exists. 3. Severity: CES is a surgical emergency; delayed diagnosis risks permanent paralysis, bladder/bowel dysfunction. 4. Risk comparison: CES carries catastrophic consequences (high severity) with substantial likelihood given clinical features. 5. The statement's recommendation for emergency MRI directly addresses ruling out this high-risk condition. Failure to image would leave catastrophic risk unmitigated. Therefore, the statement is entailed as required by risk assessment principles.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract candidates: The premise describes classic red flags for cauda equina syndrome (CES) - saddle anesthesia, urinary retention, bilateral leg weakness, and reduced reflexes. CES (B) is a critical latent diagnosis. 2. Likelihood: High clinical suspicion (multiple key symptoms present). CES remains unexcluded as no imaging exists. 3. Severity: CES is a surgical emergency; delayed diagnosis risks permanent paralysis, bladder/bowel dysfunction. 4. Risk comparison: CES carries catastrophic consequences (high severity) with substantial likelihood given clinical features. 5. The statement's recommendation for emergency MRI directly addresses ruling out this high-risk condition. Failure to image would leave catastrophic risk unmitigated. Therefore, the statement is entailed as required by risk assessment principles.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "1",
    "premise": "Outcome Measurement: Percentage of Patients Achieving FEV1 Improvement \u226515% After 6 Weeks of Inhaled Budesonide. Spirometry was performed at baseline and at Week 6. Time frame: 6 weeks. Results: 54.8% (17/31) met the improvement threshold.",
    "statement": "Inhaled budesonide improves lung function in patients.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. T (treatment) is inhaled budesonide, Y (outcome) is lung function improvement (measured via FEV1 \u226515% improvement).\n2. The premise shows 54.8% of patients achieved FEV1 improvement after 6 weeks of treatment, compared to their own baseline measurements (within-group comparison).\n3. No control group data is provided to compare against natural course/placebo effects.\n4. While FEV1 improvement suggests a positive association, causal claims require comparison against a counterfactual (control group) to rule out confounding factors.\n5. The within-group improvement constitutes correlational evidence but lacks the comparator required for strong causal inference per core principles.\n6. The statement makes a causal claim ('improves'), but the premise only demonstrates temporal association without adequate control comparison.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. T (treatment) is inhaled budesonide, Y (outcome) is lung function improvement (measured via FEV1 \u226515% improvement).\n2. The premise shows 54.8% of patients achieved FEV1 improvement after 6 weeks of treatment, compared to their own baseline measurements (within-group comparison).\n3. No control group data is provided to compare against natural course/placebo effects.\n4. While FEV1 improvement suggests a positive association, causal claims require comparison against a counterfactual (control group) to rule out confounding factors.\n5. The within-group improvement constitutes correlational evidence but lacks the comparator required for strong causal inference per core principles.\n6. The statement makes a causal claim ('improves'), but the premise only demonstrates temporal association without adequate control comparison.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "2",
    "premise": "Adverse Events Summary: Total: 6/14 (42.86%). Neutropenia 2/14 (14.29%), Peripheral neuropathy 1/14 (7.14%), Diarrhea 2/14 (14.29%), Hyponatremia 1/14 (7.14%).",
    "statement": "The treatment was effective but associated with risks to immune function and nerve health.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "The statement claims the treatment was effective and associated with risks to immune function (neutropenia) and nerve health (peripheral neuropathy). The premise reports adverse event rates but provides no data on treatment efficacy (no outcome improvement or comparator for effectiveness). Neutropenia (2/14) and peripheral neuropathy (1/14) are observed, but without a control group or baseline comparison, causal attribution to the treatment cannot be confirmed (correlation \u2260 causation per core principles). Effectiveness is unsupported, and risks lack causal evidence due to missing comparator. Both claims lack direct causal validation.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "The statement claims the treatment was effective and associated with risks to immune function (neutropenia) and nerve health (peripheral neuropathy). The premise reports adverse event rates but provides no data on treatment efficacy (no outcome improvement or comparator for effectiveness). Neutropenia (2/14) and peripheral neuropathy (1/14) are observed, but without a control group or baseline comparison, causal attribution to the treatment cannot be confirmed (correlation \u2260 causation per core principles). Effectiveness is unsupported, and risks lack causal evidence due to missing comparator. Both claims lack direct causal validation.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "3",
    "premise": "Outcome Measurement: Proportion of Patients With Resting Heart Rate <80 bpm at Week 12 After Ivabradine Therapy. Baseline average: 94 bpm. Results: 61.9% (26/42) achieved the target. Time frame: 12 weeks.",
    "statement": "Ivabradine lowers resting heart rate in patients.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": null,
    "solution_final": null,
    "is_correct": false,
    "error_info": [
      {
        "error_info": "Verification JSON error: \n{\n  \"fact_verification\": \"correct\",\n  \"fact_reasoning\": \"No unsupported facts. The solver uses data explicitly provided in the premise (baseline heart rate, post-intervention proportion achieving target, time frame) without introducing external clinical knowledge.\",\n  \"pattern_verification\": \"incorrect\",\n  \"pattern_reasoning\": \"1. The reasoning incorrectly assumes baseline comparison alone suffices for causal claims. Causal inference requires a comparator group (e.g., control/placebo) to isolate T's effect from natural variation/regression to the mean.\\n2. Minimal fix: Add 'The lack of a control group weakens causal certainty; the observed effect could reflect natural variation. A neutral conclusion (e.g., \"associated with\" instead of \"lowers\") would be more appropriate without comparator evidence.'\"\n}\n",
        "location": "agents/solvers/LLM_solver.py:68"
      },
      {
        "error_info": "Failed to solve reasoning problem: Verifier emitted invalid JSON",
        "location": "agents/solvers/LLM_solver.py:113"
      },
      {
        "error_info": "Error on id 3: Failed to solve reasoning problem: Verifier emitted invalid JSON",
        "location": "framework/skipping_planner.py:165"
      }
    ]
  },
  {
    "problem_id": "4",
    "premise": "Outcome Measurement: Percentage of Participants With Fasting Plasma Glucose <100 mg/dL After 16 Weeks of Pioglitazone. Baseline and Week 16 measurements taken. Results: 47.6% (20/42) reached the target. Time frame: 16 weeks.",
    "statement": "Pioglitazone causes a reduction in fasting plasma glucose levels.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. T = Pioglitazone, Y = fasting plasma glucose levels. The causal claim is T reduces Y.\n2. The premise reports 47.6% of participants achieved FPG <100 mg/dL at Week 16 but does NOT provide baseline values or control group data. Without knowing the baseline percentage of participants below this threshold, we cannot assess whether there was a reduction caused by T.\n3. The measurement shows post-intervention status but lacks comparative evidence (either vs baseline or vs control group) required to establish causality. A standalone endpoint measurement cannot demonstrate change over time or causal effect.\n4. No information about adverse effects or contradictory outcomes. The premise only shows a snapshot at 16 weeks without directional evidence.\n5. Conclusion: Neutral due to absence of baseline comparison or control group data needed to evaluate causal claims.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. T = Pioglitazone, Y = fasting plasma glucose levels. The causal claim is T reduces Y.\n2. The premise reports 47.6% of participants achieved FPG <100 mg/dL at Week 16 but does NOT provide baseline values or control group data. Without knowing the baseline percentage of participants below this threshold, we cannot assess whether there was a reduction caused by T.\n3. The measurement shows post-intervention status but lacks comparative evidence (either vs baseline or vs control group) required to establish causality. A standalone endpoint measurement cannot demonstrate change over time or causal effect.\n4. No information about adverse effects or contradictory outcomes. The premise only shows a snapshot at 16 weeks without directional evidence.\n5. Conclusion: Neutral due to absence of baseline comparison or control group data needed to evaluate causal claims.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "5",
    "premise": "Adverse Events: Total: 8/22 (36.36%). Elevated creatinine 2/22 (9.09%), Ankle edema 3/22 (13.64%), Hypotension 2/22 (9.09%), Fatigue 1/22 (4.55%).",
    "statement": "The treatment was effective but some patients experienced kidney function changes, swelling, and low blood pressure.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Identify T (treatment) and Y (effectiveness + adverse events). The statement makes two causal claims: treatment effectiveness (positive outcome) and causation of specific adverse events (negative outcomes).\n2. The premise only reports adverse event rates (36.36% total) including elevated creatinine (kidney function changes), ankle edema (swelling), and hypotension (low BP). No effectiveness metrics (e.g., efficacy outcomes vs control) are mentioned.\n3. No control group or baseline comparison exists for either claim. Adverse event rates alone don't establish causation without knowing background rates in untreated populations.\n4. The premise lacks evidence about treatment effectiveness (no outcome improvement data) and lacks comparator data to confirm the adverse events were caused by treatment rather than occurring naturally.\n5. While the adverse events mentioned in the statement match those in the premise, causal attribution requires control group comparison which is absent. Effectiveness claim is entirely unsupported.\n6. Neutral because neither causal claim (effectiveness nor adverse event causation) can be confirmed/refuted without comparative evidence.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Identify T (treatment) and Y (effectiveness + adverse events). The statement makes two causal claims: treatment effectiveness (positive outcome) and causation of specific adverse events (negative outcomes).\n2. The premise only reports adverse event rates (36.36% total) including elevated creatinine (kidney function changes), ankle edema (swelling), and hypotension (low BP). No effectiveness metrics (e.g., efficacy outcomes vs control) are mentioned.\n3. No control group or baseline comparison exists for either claim. Adverse event rates alone don't establish causation without knowing background rates in untreated populations.\n4. The premise lacks evidence about treatment effectiveness (no outcome improvement data) and lacks comparator data to confirm the adverse events were caused by treatment rather than occurring naturally.\n5. While the adverse events mentioned in the statement match those in the premise, causal attribution requires control group comparison which is absent. Effectiveness claim is entirely unsupported.\n6. Neutral because neither causal claim (effectiveness nor adverse event causation) can be confirmed/refuted without comparative evidence.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "6",
    "premise": "Adverse Events Summary: Total: 4/12 (33.33%). Headache 2/12 (16.67%), Pruritus 1/12 (8.33%), Mild anemia 1/12 (8.33%). All events were Grade 1 or 2.",
    "statement": "The drug was effective and well tolerated, with only mild side effects reported.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "The statement makes two claims: (1) effectiveness (causal relationship T \u2192 improved outcome) and (2) tolerability (T \u2192 only mild side effects). The premise only reports adverse event grades (all Grade 1/2) and rates (33.33% total), which directly confirms the tolerability claim about mild side effects. However, the premise contains no efficacy data (e.g., disease improvement metrics, control group comparison, or baseline measurements) to support the effectiveness claim. Since causal claims require evidence of comparator outcomes for validation, the effectiveness portion remains unsubstantiated. While the tolerability claim is entailed, the combined statement requires both claims to be true. The absence of efficacy evidence makes the overall label neutral.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "The statement makes two claims: (1) effectiveness (causal relationship T \u2192 improved outcome) and (2) tolerability (T \u2192 only mild side effects). The premise only reports adverse event grades (all Grade 1/2) and rates (33.33% total), which directly confirms the tolerability claim about mild side effects. However, the premise contains no efficacy data (e.g., disease improvement metrics, control group comparison, or baseline measurements) to support the effectiveness claim. Since causal claims require evidence of comparator outcomes for validation, the effectiveness portion remains unsubstantiated. While the tolerability claim is entailed, the combined statement requires both claims to be true. The absence of efficacy evidence makes the overall label neutral.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "7",
    "premise": "Treatment-Emergent Adverse Events: 5/16 (31.25%). Hyperkalemia 1/16 (6.25%), Dizziness 2/16 (12.50%), Palpitations 1/16 (6.25%), Constipation 1/16 (6.25%).",
    "statement": "The treatment improved outcomes but some patients experienced electrolyte imbalances and cardiovascular symptoms.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Identify T (treatment) and Y (outcomes): The statement makes two causal claims - improved outcomes (positive effect) and adverse events (negative effects).\n2. Premise analysis: Only reports adverse event rates (31.25% overall) including hyperkalemia (electrolyte imbalance) and palpitations (cardiovascular symptom). No outcomes data or control group comparison exists.\n3. Causal validation: \n   - 'Improved outcomes' requires evidence of benefit compared to baseline/control (absent in premise) \u2192 unsupported\n   - Adverse events are reported but without control group rates, we cannot confirm causation (though labeled 'treatment-emergent', core principles require comparator for causal claims)\n4. Directionality mismatch: The premise contains evidence of harm (adverse events) but no evidence of benefit. The positive claim ('improved') contradicts the absence of benefit evidence.\n5. Conclusion: The statement combines an unsupported positive claim with reported adverse events. Without comparative data for either claim, the positive assertion is contradicted while the adverse event report remains non-causal correlation.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Identify T (treatment) and Y (outcomes): The statement makes two causal claims - improved outcomes (positive effect) and adverse events (negative effects).\n2. Premise analysis: Only reports adverse event rates (31.25% overall) including hyperkalemia (electrolyte imbalance) and palpitations (cardiovascular symptom). No outcomes data or control group comparison exists.\n3. Causal validation: \n   - 'Improved outcomes' requires evidence of benefit compared to baseline/control (absent in premise) \u2192 unsupported\n   - Adverse events are reported but without control group rates, we cannot confirm causation (though labeled 'treatment-emergent', core principles require comparator for causal claims)\n4. Directionality mismatch: The premise contains evidence of harm (adverse events) but no evidence of benefit. The positive claim ('improved') contradicts the absence of benefit evidence.\n5. Conclusion: The statement combines an unsupported positive claim with reported adverse events. Without comparative data for either claim, the positive assertion is contradicted while the adverse event report remains non-causal correlation.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": false,
    "error_info": []
  },
  {
    "problem_id": "8",
    "premise": "Outcome: Percentage of patients achieving serum uric acid <6 mg/dL after 10 weeks of allopurinol. Results: 69.2% (18/26) achieved the target. Time frame: 10 weeks.",
    "statement": "Allopurinol effectively lowers serum uric acid in most patients.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Identify T (allopurinol) and Y (serum uric acid <6 mg/dL).\n2. Premise reports 69.2% achievement rate in treatment group but lacks control group or baseline data.\n3. Causal claims require comparison (e.g., vs placebo or pre-treatment levels) to establish efficacy.\n4. While the result suggests association, absence of comparator prevents causal inference.\n5. 'Effectively lowers' implies causation, but premise only shows post-treatment outcomes without reference point.\n6. Neutral because correlation \u2260 causation without control/baseline evidence.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Identify T (allopurinol) and Y (serum uric acid <6 mg/dL).\n2. Premise reports 69.2% achievement rate in treatment group but lacks control group or baseline data.\n3. Causal claims require comparison (e.g., vs placebo or pre-treatment levels) to establish efficacy.\n4. While the result suggests association, absence of comparator prevents causal inference.\n5. 'Effectively lowers' implies causation, but premise only shows post-treatment outcomes without reference point.\n6. Neutral because correlation \u2260 causation without control/baseline evidence.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "9",
    "premise": "Outcome: Rate of complete lesion clearance at Week 4 following topical 5-fluorouracil application for actinic keratosis. 55% (11/20) achieved complete clearance. Time frame: 4 weeks.",
    "statement": "Topical 5-fluorouracil accelerates lesion clearance in actinic keratosis.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Causal claim identified: 'accelerates' implies T (5-fluorouracil) causes faster Y (lesion clearance).\n2. Premise only reports absolute clearance rate (55%) at 4 weeks in treatment group with no comparator (control group or baseline rate without treatment).\n3. No evidence of clearance speed/duration compared to natural history or alternative treatments.\n4. Acceleration requires temporal comparison (e.g., faster than expected/protocol-defined timelines), which is absent.\n5. Core principle violation: Causal claims about treatment effects require controlled comparisons. Single-arm data cannot support causal acceleration claims.\n6. Conclusion: Neutral due to lack of comparator needed to establish causal acceleration.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Causal claim identified: 'accelerates' implies T (5-fluorouracil) causes faster Y (lesion clearance).\n2. Premise only reports absolute clearance rate (55%) at 4 weeks in treatment group with no comparator (control group or baseline rate without treatment).\n3. No evidence of clearance speed/duration compared to natural history or alternative treatments.\n4. Acceleration requires temporal comparison (e.g., faster than expected/protocol-defined timelines), which is absent.\n5. Core principle violation: Causal claims about treatment effects require controlled comparisons. Single-arm data cannot support causal acceleration claims.\n6. Conclusion: Neutral due to lack of comparator needed to establish causal acceleration.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "10",
    "premise": "Outcome: Percentage of participants with \u226550% reduction in weekly migraine days at Week 8 following galcanezumab injections. 62.5% (15/24) met the reduction threshold. No control group included.",
    "statement": "Galcanezumab reduces migraine frequency significantly by Week 8.",
    "label": "neutral",
    "gt_problem_type": "causal",
    "solution_history": [
      {
        "reasoning": "1. Identify T (galcanezumab) and Y (migraine frequency reduction).\n2. Premise shows 62.5% achieved \u226550% reduction but lacks control group/baseline comparison.\n3. Causal claims require evidence of effect relative to control or baseline (core principle 2).\n4. Without knowing natural variation/placebo effect rates, observed reduction could be due to treatment or other factors.\n5. While the outcome is favorable, absence of comparator prevents causal attribution (correlation \u2260 causation principle).\n6. No evidence direction can be established relative to untreated scenario.\n7. Therefore, as per decision procedure: insufficient control comparison \u2192 neutral.",
        "pred": "neutral",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Identify T (galcanezumab) and Y (migraine frequency reduction).\n2. Premise shows 62.5% achieved \u226550% reduction but lacks control group/baseline comparison.\n3. Causal claims require evidence of effect relative to control or baseline (core principle 2).\n4. Without knowing natural variation/placebo effect rates, observed reduction could be due to treatment or other factors.\n5. While the outcome is favorable, absence of comparator prevents causal attribution (correlation \u2260 causation principle).\n6. No evidence direction can be established relative to untreated scenario.\n7. Therefore, as per decision procedure: insufficient control comparison \u2192 neutral.",
      "pred": "neutral",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "21",
    "premise": "70-year-old male with chronic lymphocytic leukemia receiving fludarabine 120mg/m\u00b2 intravenously daily for 14 consecutive days per cycle.",
    "statement": "The treatment is expected to induce remission, improve blood counts, and prolong survival.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: fludarabine 120mg/m\u00b2 daily \u00d714 days for CLL in elderly patient.\n2. Clinical guidelines show standard fludarabine dosing for CLL is 25mg/m\u00b2/day \u00d75 days/cycle. The stated dose (120mg/m\u00b2) is 4.8\u00d7 higher than maximum recommended dose.\n3. High-dose fludarabine causes severe cumulative myelosuppression and neurotoxicity, particularly in older patients. The 14-day schedule further exceeds safety limits.\n4. This regimen would likely cause life-threatening toxicity rather than therapeutic benefit, contradicting the statement's positive outcomes.\n5. Dependency violation: dose \u00d7 schedule \u00d7 age interaction makes the described treatment unsafe/non-therapeutic.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: fludarabine 120mg/m\u00b2 daily \u00d714 days for CLL in elderly patient.\n2. Clinical guidelines show standard fludarabine dosing for CLL is 25mg/m\u00b2/day \u00d75 days/cycle. The stated dose (120mg/m\u00b2) is 4.8\u00d7 higher than maximum recommended dose.\n3. High-dose fludarabine causes severe cumulative myelosuppression and neurotoxicity, particularly in older patients. The 14-day schedule further exceeds safety limits.\n4. This regimen would likely cause life-threatening toxicity rather than therapeutic benefit, contradicting the statement's positive outcomes.\n5. Dependency violation: dose \u00d7 schedule \u00d7 age interaction makes the described treatment unsafe/non-therapeutic.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "22",
    "premise": "55-year-old female with HER2-positive breast cancer receiving trastuzumab 40mg/kg intravenously every 3 weeks for 8 cycles.",
    "statement": "The therapy is expected to control tumor growth and improve long-term prognosis.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: HER2+ breast cancer, trastuzumab 40mg/kg q3w x8 cycles. Statement claims tumor control/prognosis improvement.\n2. Check dependencies: Trastuzumab's standard dose is 8mg/kg loading \u2192 6mg/kg q3w maintenance. The premise uses 40mg/kg (5x higher), which exceeds maximum safe dose thresholds.\n3. Schedule conflict: Even if dose error (e.g., typo), 8 cycles (24 weeks total) is below minimum duration (standard adjuvant therapy is 1 year).\n4. Combined effect: Incorrect dose + insufficient duration violate pharmacokinetic/pharmacodynamic requirements for efficacy. This makes tumor control/prognosis improvement biologically implausible.\n5. Contradiction arises from protocol deviations that nullify expected therapeutic outcomes.",
        "pred": "contradiction",
        "fact_verification": "incorrect",
        "reasoning_verification": "incorrect",
        "overall_verification": false
      },
      {
        "reasoning": "1. Extract factors: HER2+ breast cancer, trastuzumab 40mg/kg q3w x8 cycles. Statement claims tumor control/prognosis improvement.\n2. Dose analysis: The premise specifies 40mg/kg. While standard adjuvant therapy uses 6mg/kg q3w, the premise does not confirm metastatic vs. adjuvant context. Experimental neoadjuvant protocols may use escalated doses (e.g., 40mg/kg), so dose alone cannot invalidate efficacy without explicit pharmacokinetic contradictions.\n3. Duration analysis: 8 cycles (24 weeks) is below the standard 1-year (52-week) adjuvant duration required for proven long-term efficacy. No premise data supports shorter duration equivalency.\n4. Dependency check: Insufficient duration independently violates the minimum requirement for trastuzumab\u2019s established prognostic benefit in HER2+ breast cancer, regardless of dose.\n5. Violation test: The statement\u2019s 'improve long-term prognosis' depends on protocol adherence to evidence-based duration. A 24-week regimen directly contradicts this requirement.",
        "pred": "contradiction"
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: HER2+ breast cancer, trastuzumab 40mg/kg q3w x8 cycles. Statement claims tumor control/prognosis improvement.\n2. Dose analysis: The premise specifies 40mg/kg. While standard adjuvant therapy uses 6mg/kg q3w, the premise does not confirm metastatic vs. adjuvant context. Experimental neoadjuvant protocols may use escalated doses (e.g., 40mg/kg), so dose alone cannot invalidate efficacy without explicit pharmacokinetic contradictions.\n3. Duration analysis: 8 cycles (24 weeks) is below the standard 1-year (52-week) adjuvant duration required for proven long-term efficacy. No premise data supports shorter duration equivalency.\n4. Dependency check: Insufficient duration independently violates the minimum requirement for trastuzumab\u2019s established prognostic benefit in HER2+ breast cancer, regardless of dose.\n5. Violation test: The statement\u2019s 'improve long-term prognosis' depends on protocol adherence to evidence-based duration. A 24-week regimen directly contradicts this requirement.",
      "pred": "contradiction"
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "23",
    "premise": "3-year-old child diagnosed with acute myeloid leukemia receiving cytarabine 1500mg/m\u00b2 intravenously every 12 hours for 14 days.",
    "statement": "The treatment is expected to induce remission and improve the child\u2019s survival chances.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "The premise specifies a 3-year-old child with AML receiving cytarabine 1500mg/m\u00b2 every 12 hours for 14 days. High-dose cytarabine (\u22651g/m\u00b2/dose) is part of standard AML regimens, but typical pediatric protocols use shorter durations (e.g., 3-6 days) due to neurotoxicity risks. A 14-day schedule at this constraint violates established safety limits for cumulative exposure, increasing toxicity without proven survival benefit. Since the described regimen exceeds safe/effective duration thresholds, the claim about improving survival contradicts known clinical guidelines for pediatric cytarabine administration.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "The premise specifies a 3-year-old child with AML receiving cytarabine 1500mg/m\u00b2 every 12 hours for 14 days. High-dose cytarabine (\u22651g/m\u00b2/dose) is part of standard AML regimens, but typical pediatric protocols use shorter durations (e.g., 3-6 days) due to neurotoxicity risks. A 14-day schedule at this constraint violates established safety limits for cumulative exposure, increasing toxicity without proven survival benefit. Since the described regimen exceeds safe/effective duration thresholds, the claim about improving survival contradicts known clinical guidelines for pediatric cytarabine administration.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "24",
    "premise": "68-year-old male with hepatocellular carcinoma and severe liver cirrhosis (Child-Pugh C) receiving sorafenib 1600mg orally twice daily.",
    "statement": "The patient is expected to benefit from slowed tumor progression and improved overall survival.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: Premise includes hepatocellular carcinoma (indication for sorafenib), Child-Pugh C cirrhosis (severe liver impairment), and sorafenib 1600mg twice daily (double standard dose).\n2. Identify dependencies: Child-Pugh C cirrhosis contraindicates full-dose sorafenib (requires dose reduction/discontinuation per prescribing guidelines).\n3. Evaluate interactions: Severe liver impairment (Child-Pugh C) reduces sorafenib metabolism, increasing toxicity risk while decreasing efficacy. The 1600mg dose (standard is 400mg BID) would be unsafe and ineffective in this population.\n4. Clinical trial evidence shows sorafenib is not recommended in Child-Pugh C patients due to lack of survival benefit and increased adverse events.\n5. Statement claims expected benefit from a contraindicated regimen \u2192 explicit mismatch between liver function status and therapeutic expectation.",
        "pred": "contradiction",
        "fact_verification": "incorrect",
        "reasoning_verification": "correct",
        "overall_verification": false
      },
      {
        "reasoning": "1. Extract factors: Premise includes hepatocellular carcinoma (indication for sorafenib), Child-Pugh C cirrhosis (severe liver impairment), and sorafenib 1600mg twice daily (quadruple standard dose, as the standard is 400mg BID).\n2. Identify dependencies: Child-Pugh C cirrhosis contraindicates full-dose sorafenib per guidelines, requiring dose reduction/discontinuation.\n3. Evaluate interactions: Severe liver impairment reduces sorafenib metabolism, increasing toxicity and decreasing efficacy. The 1600mg BID dose (quadruple standard) would be unsafe and ineffective in Child-Pugh C patients.\n4. Clinical evidence confirms sorafenib lacks survival benefit and increases adverse events in Child-Pugh C patients.\n5. Statement claims expected benefit from a contraindicated regimen (quadruple dose in severe impairment) \u2192 explicit mismatch between liver function status and therapeutic expectation.",
        "pred": "contradiction"
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: Premise includes hepatocellular carcinoma (indication for sorafenib), Child-Pugh C cirrhosis (severe liver impairment), and sorafenib 1600mg twice daily (quadruple standard dose, as the standard is 400mg BID).\n2. Identify dependencies: Child-Pugh C cirrhosis contraindicates full-dose sorafenib per guidelines, requiring dose reduction/discontinuation.\n3. Evaluate interactions: Severe liver impairment reduces sorafenib metabolism, increasing toxicity and decreasing efficacy. The 1600mg BID dose (quadruple standard) would be unsafe and ineffective in Child-Pugh C patients.\n4. Clinical evidence confirms sorafenib lacks survival benefit and increases adverse events in Child-Pugh C patients.\n5. Statement claims expected benefit from a contraindicated regimen (quadruple dose in severe impairment) \u2192 explicit mismatch between liver function status and therapeutic expectation.",
      "pred": "contradiction"
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "25",
    "premise": "49-year-old female with metastatic colorectal cancer receiving irinotecan 1500mg/m\u00b2 weekly for 8 weeks.",
    "statement": "The treatment is expected to reduce metastatic lesions and improve disease control.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: The premise specifies irinotecan 1500mg/m\u00b2 weekly. Standard irinotecan regimens for colorectal cancer are 125-180 mg/m\u00b2 weekly or biweekly. 2. Identify dependency: The stated dose (1500mg/m\u00b2) exceeds maximum tolerated doses (>750mg/m\u00b2 cumulative per cycle). 3. Violation: This extreme overdose would cause life-threatening toxicity rather than therapeutic effect. 4. Interaction: Impossible dose invalidates any expected treatment benefit. 5. Conclusion: The claimed outcome directly contradicts the pharmacological reality of the described regimen.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: The premise specifies irinotecan 1500mg/m\u00b2 weekly. Standard irinotecan regimens for colorectal cancer are 125-180 mg/m\u00b2 weekly or biweekly. 2. Identify dependency: The stated dose (1500mg/m\u00b2) exceeds maximum tolerated doses (>750mg/m\u00b2 cumulative per cycle). 3. Violation: This extreme overdose would cause life-threatening toxicity rather than therapeutic effect. 4. Interaction: Impossible dose invalidates any expected treatment benefit. 5. Conclusion: The claimed outcome directly contradicts the pharmacological reality of the described regimen.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "26",
    "premise": "80-year-old male with chronic kidney disease (eGFR 15 mL/min/1.73m\u00b2) and multiple myeloma receiving cisplatin 200mg/m\u00b2 daily for 5 consecutive days.",
    "statement": "The regimen is expected to achieve disease control and extend progression-free survival.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: 80yo male, CKD (eGFR 15), multiple myeloma, cisplatin 200mg/m\u00b2 daily \u00d75 days.\n2. Identify dependencies: Cisplatin requires adequate renal function (contraindicated when eGFR <30). Dose of 200mg/m\u00b2 exceeds maximum recommended dose (typically 100mg/m\u00b2 per cycle). Daily \u00d75 days (1000mg/m\u00b2 total) far exceeds cumulative nephrotoxicity thresholds.\n3. Severe CKD (eGFR 15) makes cisplatin contraindicated regardless of dose. Multiple myeloma patients often have baseline renal impairment requiring dose adjustments.\n4. The regimen violates both renal function contraindication and maximum dose constraints. This combination would likely cause life-threatening toxicity rather than therapeutic benefit.\n5. Statement claims expected efficacy, but fundamental pharmacokinetic/pharmacodynamic constraints make this impossible \u2192 contradiction.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: 80yo male, CKD (eGFR 15), multiple myeloma, cisplatin 200mg/m\u00b2 daily \u00d75 days.\n2. Identify dependencies: Cisplatin requires adequate renal function (contraindicated when eGFR <30). Dose of 200mg/m\u00b2 exceeds maximum recommended dose (typically 100mg/m\u00b2 per cycle). Daily \u00d75 days (1000mg/m\u00b2 total) far exceeds cumulative nephrotoxicity thresholds.\n3. Severe CKD (eGFR 15) makes cisplatin contraindicated regardless of dose. Multiple myeloma patients often have baseline renal impairment requiring dose adjustments.\n4. The regimen violates both renal function contraindication and maximum dose constraints. This combination would likely cause life-threatening toxicity rather than therapeutic benefit.\n5. Statement claims expected efficacy, but fundamental pharmacokinetic/pharmacodynamic constraints make this impossible \u2192 contradiction.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "27",
    "premise": "62-year-old female with ovarian cancer receiving carboplatin at an AUC of 20 every 3 weeks for 6 cycles.",
    "statement": "The treatment is expected to shrink tumor burden and prolong overall survival.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: Premise specifies carboplatin at AUC 20 (extremely high dose) for ovarian cancer. Statement claims expected efficacy.\n2. Clinical dependency: Standard carboplatin AUC dosing in ovarian cancer is 5-7 (Calvert formula). AUC 20 exceeds maximum tolerated doses (>99th percentile).\n3. Interaction analysis: Severely supratherapeutic dosing would cause dose-limiting toxicities (myelosuppression, nephrotoxicity) requiring treatment discontinuation before completing 6 cycles, making tumor response/survival benefit biologically implausible.\n4. Violation: Impossible dose-efficacy relationship at stated AUC invalidates the statement's claimed outcomes.",
        "pred": "contradiction",
        "fact_verification": "incorrect",
        "reasoning_verification": "correct",
        "overall_verification": false
      },
      {
        "reasoning": "1. Extract factors: Premise specifies carboplatin at AUC 20 (exceeding standard dosing) for ovarian cancer. Statement claims expected efficacy.\n2. Clinical dependency: Standard carboplatin AUC dosing in ovarian cancer is 5-7 (Calvert formula, general clinical knowledge). AUC 20 exceeds this range.\n3. Interaction analysis: Supratherapeutic dosing would likely cause dose-limiting toxicities (myelosuppression, nephrotoxicity), risking treatment discontinuation before completing 6 cycles. Incomplete treatment reduces likelihood of achieving tumor response/survival benefit.\n4. Violation test: The premise's AUC 20 directly conflicts with dose tolerability constraints required to complete therapy and realize efficacy outcomes. This interaction invalidates the statement's claimed outcomes.",
        "pred": "contradiction"
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: Premise specifies carboplatin at AUC 20 (exceeding standard dosing) for ovarian cancer. Statement claims expected efficacy.\n2. Clinical dependency: Standard carboplatin AUC dosing in ovarian cancer is 5-7 (Calvert formula, general clinical knowledge). AUC 20 exceeds this range.\n3. Interaction analysis: Supratherapeutic dosing would likely cause dose-limiting toxicities (myelosuppression, nephrotoxicity), risking treatment discontinuation before completing 6 cycles. Incomplete treatment reduces likelihood of achieving tumor response/survival benefit.\n4. Violation test: The premise's AUC 20 directly conflicts with dose tolerability constraints required to complete therapy and realize efficacy outcomes. This interaction invalidates the statement's claimed outcomes.",
      "pred": "contradiction"
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "28",
    "premise": "58-year-old male with small cell lung cancer receiving etoposide 1500mg/m\u00b2 daily for 10 consecutive days.",
    "statement": "The regimen is expected to induce tumor regression and improve clinical outcomes.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: Premise specifies etoposide 1500mg/m\u00b2 daily \u00d710 days for small cell lung cancer. Statement claims tumor regression/improved outcomes.\n2. Check constraints: Standard etoposide dosing for SCLC is 100-120mg/m\u00b2 IV daily \u00d73 days (with cisplatin) or 200mg/m\u00b2 PO days 1-5 in 21-day cycles. The stated dose (1500mg/m\u00b2 \u00d710) exceeds maximum tolerated doses (>3600mg/m\u00b2 cumulative per cycle causes fatal myelosuppression).\n3. Dependency analysis: Extreme overdose (10\u00d7 standard daily dose) violates safe administration limits. This invalidates any therapeutic benefit claim due to inevitable life-threatening toxicity.\n4. Interaction: Dose-unit-schedule combination creates impossible regimen (contraindicated by hematologic toxicity thresholds).",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: Premise specifies etoposide 1500mg/m\u00b2 daily \u00d710 days for small cell lung cancer. Statement claims tumor regression/improved outcomes.\n2. Check constraints: Standard etoposide dosing for SCLC is 100-120mg/m\u00b2 IV daily \u00d73 days (with cisplatin) or 200mg/m\u00b2 PO days 1-5 in 21-day cycles. The stated dose (1500mg/m\u00b2 \u00d710) exceeds maximum tolerated doses (>3600mg/m\u00b2 cumulative per cycle causes fatal myelosuppression).\n3. Dependency analysis: Extreme overdose (10\u00d7 standard daily dose) violates safe administration limits. This invalidates any therapeutic benefit claim due to inevitable life-threatening toxicity.\n4. Interaction: Dose-unit-schedule combination creates impossible regimen (contraindicated by hematologic toxicity thresholds).",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "29",
    "premise": "4-month-old infant diagnosed with neuroblastoma receiving doxorubicin 80mg/m\u00b2 daily for 7 days.",
    "statement": "The treatment is expected to achieve tumor shrinkage and improve prognosis.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: doxorubicin 80mg/m\u00b2 daily \u00d77 days (total 560mg/m\u00b2) in a 4-month-old infant with neuroblastoma.\n2. Check dosing validity: Pediatric doxorubicin cumulative doses typically range 300-400mg/m\u00b2 lifetime (with lower thresholds for infants). This regimen exceeds safe limits in 1 week.\n3. Dependency analysis: Extreme overdosing (560mg/m\u00b2) creates cardiotoxicity risk that would negate therapeutic benefit, making tumor response claims invalid.\n4. Contraindication triggered: This dose schedule is incompatible with safe pediatric oncology practice, creating a fundamental contradiction between stated outcome expectations and treatment reality.",
        "pred": "contradiction",
        "fact_verification": "incorrect",
        "reasoning_verification": "incorrect",
        "overall_verification": false
      },
      {
        "reasoning": "1. Extract factors: 4-month-old infant with neuroblastoma receiving doxorubicin 80mg/m\u00b2 daily for 7 days (total 560mg/m\u00b2).\n2. Check single-dose validity: Per clinical standards, infant doxorubicin dosing is 15-30mg/m\u00b2 weekly. This regimen delivers 80mg/m\u00b2 daily \u00d77 days = 560mg/m\u00b2/week - a 18.7-37.3x overdose compared to maximum weekly standards.\n3. Dependency analysis: Such extreme overdose would cause acute fatal toxicity (not merely long-term cardiotoxicity), making administration of this regimen clinically impossible. Survival to achieve tumor response would be precluded.\n4. Violation test: The stated expectation of tumor shrinkage/prognosis improvement fundamentally contradicts the treatment's fatal iatrogenic consequences. No clinical scenario allows simultaneous administration and therapeutic benefit at this dose.",
        "pred": "contradiction"
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: 4-month-old infant with neuroblastoma receiving doxorubicin 80mg/m\u00b2 daily for 7 days (total 560mg/m\u00b2).\n2. Check single-dose validity: Per clinical standards, infant doxorubicin dosing is 15-30mg/m\u00b2 weekly. This regimen delivers 80mg/m\u00b2 daily \u00d77 days = 560mg/m\u00b2/week - a 18.7-37.3x overdose compared to maximum weekly standards.\n3. Dependency analysis: Such extreme overdose would cause acute fatal toxicity (not merely long-term cardiotoxicity), making administration of this regimen clinically impossible. Survival to achieve tumor response would be precluded.\n4. Violation test: The stated expectation of tumor shrinkage/prognosis improvement fundamentally contradicts the treatment's fatal iatrogenic consequences. No clinical scenario allows simultaneous administration and therapeutic benefit at this dose.",
      "pred": "contradiction"
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "30",
    "premise": "67-year-old patient with advanced gastric cancer receiving 5-fluorouracil 2500mg/m\u00b2 intravenously daily for 14 consecutive days.",
    "statement": "The therapy is expected to slow disease progression and improve survival rates.",
    "label": "contradiction",
    "gt_problem_type": "comp",
    "solution_history": [
      {
        "reasoning": "1. Extract factors: Premise specifies 5-fluorouracil 2500mg/m\u00b2 daily \u00d714 days for advanced gastric cancer. Statement claims expected efficacy (slowing progression/survival benefit).\n2. Clinical validation: Standard 5-FU regimens for gastric cancer typically use lower doses (e.g., 1000mg/m\u00b2/day \u00d74-5 days in combination therapies) or continuous infusions (e.g., 1000mg/m\u00b2/day \u00d7120hrs).\n3. Dependency check: The stated dose (2500mg/m\u00b2/day \u00d714 = 35,000mg/m\u00b2/cycle) exceeds maximum tolerated doses (MTD) for 5-FU, which is ~2600mg/m\u00b2/week in most regimens. This schedule would cause severe toxicity (e.g., myelosuppression, mucositis), making it clinically ineffective and unsafe.\n4. Interaction between dose/duration invalidates therapeutic intent: Excessive cumulative dose directly contradicts the statement's claimed benefit due to predictable harm outweighing efficacy.",
        "pred": "contradiction",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Extract factors: Premise specifies 5-fluorouracil 2500mg/m\u00b2 daily \u00d714 days for advanced gastric cancer. Statement claims expected efficacy (slowing progression/survival benefit).\n2. Clinical validation: Standard 5-FU regimens for gastric cancer typically use lower doses (e.g., 1000mg/m\u00b2/day \u00d74-5 days in combination therapies) or continuous infusions (e.g., 1000mg/m\u00b2/day \u00d7120hrs).\n3. Dependency check: The stated dose (2500mg/m\u00b2/day \u00d714 = 35,000mg/m\u00b2/cycle) exceeds maximum tolerated doses (MTD) for 5-FU, which is ~2600mg/m\u00b2/week in most regimens. This schedule would cause severe toxicity (e.g., myelosuppression, mucositis), making it clinically ineffective and unsafe.\n4. Interaction between dose/duration invalidates therapeutic intent: Excessive cumulative dose directly contradicts the statement's claimed benefit due to predictable harm outweighing efficacy.",
      "pred": "contradiction",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  },
  {
    "problem_id": "40",
    "premise": "A 49-year-old man with a history of poorly controlled hypertension develops sudden severe tearing chest pain radiating to his back while lifting a heavy box. He is diaphoretic and mildly hypertensive on arrival. ECG shows no acute ischemic changes, and initial troponin is normal. No CT angiography or echocardiography has been performed.",
    "statement": "Aortic dissection must be urgently excluded.",
    "label": "entailment",
    "gt_problem_type": "risk",
    "solution_history": [
      {
        "reasoning": "1. Candidates: Aortic dissection (high-risk latent diagnosis) based on sudden tearing chest/back pain in hypertensive patient. 2. Likelihood: High - classic presentation (tearing pain, risk factors) despite normal ECG/troponin (which don't rule out dissection). 3. Severity: Catastrophic (immediately life-threatening if untreated). 4. Risk assessment: High likelihood \u00d7 extreme severity = highest priority risk. 5. Management implication: Statement correctly identifies that this diagnosis remains not excluded (no CTA/echo) and requires urgent workup. Failure to exclude would leave catastrophic risk unaddressed. 6. Conclusion: Statement aligns with necessary risk mitigation.",
        "pred": "entailment",
        "fact_verification": "correct",
        "reasoning_verification": "correct",
        "overall_verification": true
      }
    ],
    "solution_final": {
      "reasoning": "1. Candidates: Aortic dissection (high-risk latent diagnosis) based on sudden tearing chest/back pain in hypertensive patient. 2. Likelihood: High - classic presentation (tearing pain, risk factors) despite normal ECG/troponin (which don't rule out dissection). 3. Severity: Catastrophic (immediately life-threatening if untreated). 4. Risk assessment: High likelihood \u00d7 extreme severity = highest priority risk. 5. Management implication: Statement correctly identifies that this diagnosis remains not excluded (no CTA/echo) and requires urgent workup. Failure to exclude would leave catastrophic risk unaddressed. 6. Conclusion: Statement aligns with necessary risk mitigation.",
      "pred": "entailment",
      "fact_verification": "correct",
      "reasoning_verification": "correct",
      "overall_verification": true
    },
    "is_correct": true,
    "error_info": []
  }
]